<DOC>
	<DOC>NCT01093963</DOC>
	<brief_summary>The specific aim of this study is to evaluate the efficacy and tolerability of a stimulant (lisdexamfetamine) in the adjunctive treatment of bipolar disorder.</brief_summary>
	<brief_title>Efficacy Study of Lisdexamfetamine to Treat Bipolar Depression</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Lisdexamfetamine Dimesylate</mesh_term>
	<criteria>Men and women, through the ages of 18 and 55 years, inclusive. Women who are pregnant, lactating, or of childbearing potential who are not using adequate contraceptive measures. Subjects who are displaying clinically significant homicidality or suicidality Clinically unstable medical disease, including cardiovascular, hepatic, renal, gastrointestinal, pulmonary, metabolic, endocrine or other systemic disease. Subjects should be biochemically euthyroid to enter the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>